Inside a Breakthrough HER2 Immunotherapy for PMO with OS Therapies’ Paul Romness

We love to hear from our listeners. Send us a message. In episode 122 of Cell & Gene: The Podcast, Host Erin Harris talks to Paul Romness, CEO of OS Therapies, to learn the company’s mission to address the severe unmet need in pulmonary metastatic osteosarcoma (PMO), a rare pediatric cancer with no established standard of care once it metastasizes. Romness explains how OS Therapies’ off-the-shelf HER2-targeted immunotherapy aims to significantly improve outcomes by stimulating a robust immune response with minimal side effects. He highlights results from a multicenter Phase 2B trial showing markedly improved overall survival rates compared to historical outcomes, details the company’s constructive regulatory interactions with the FDA, and underscores the value of comparative canine biomarkers in development.

You can listen to Inside a Breakthrough HER2 Immunotherapy for PMO with OS Therapies’ Paul Romness online on Radio and Podcast. Open the player on this page to stream the available audio.

Inside a Breakthrough HER2 Immunotherapy for PMO with OS Therapies’ Paul Romness is an episode from Cell & Gene: The Podcast by Erin Harris.

This episode is 14:20 long.

This episode was published on Feb 12, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Cell & Gene: The Podcast when more episodes are available from the podcast feed.